---
title: "Acute Coronary Syndrome (ACS) Clinical Trials | Amavita Research"
url: https://md.amavitaresearch.com/therapeutic-areas/acute-coronary-syndrome
canonical: https://www.amavitaresearch.com/therapeutic-areas/acute-coronary-syndrome
schema_type: MedicalCondition
last_updated: 2026-05-13
---

# Acute Coronary Syndrome Clinical Trials

Amavita Research enrolls post-event ACS patients into pivotal Phase 3 trials and post-MI optimization studies.

## Currently enrolling

- **LIBREXIA-ACS** — Pfizer C4921003, Phase 3 acute coronary syndrome. https://www.amavitaresearch.com/trials/librexia-acs

## Patient profile

- Recent acute MI (NSTEMI or STEMI) within protocol-defined window
- Post-PCI with successful revascularization
- Symptomatic angina post-event
- Stable enough for outpatient enrollment

## What patients can expect

Free trial-related care, study drug, and follow-up visits. Co-management with referring interventional cardiologist or primary care physician.

## Sponsor decision criteria

- Walk-in cardiology practice flow captures post-discharge ACS patients in routine follow-up
- Interventional PI on staff
- Same-day troponin, hs-CRP, lipid panel processing
- Cath-lab access for repeat procedures

## Key links

- LIBREXIA-ACS trial detail: https://www.amavitaresearch.com/trials/librexia-acs
- Patient guide: https://www.amavitaresearch.com/blog/acute-coronary-syndrome-clinical-trials-patient-guide
- Site capabilities: https://www.amavitaresearch.com/capabilities
- Contact: https://www.amavitaresearch.com/contact-patient